Pharmaceuticals Ltd.

Revolutionary treatment for 

Pre-term labor & Labor induction 

Affects millions of women and newborn!

Bioterm Pharmaceuticals Ltd. is the developer of novel therapeutics for the treatment and prevention of pre-term labor and for the induction of labor that cause severe morbidity of millions of newborn worldwide.

The Company has patented the use of two molecules, its Preventerm molecule for the prevention of pre-term labor (PCT, pending) and its Inducterm molecule (approved patent) for labor induction.

Both molecules have been approved for therapy for unrelated indications, allowing BT a substantial acceleration of regulatory approvals. 

BT is currently seeking an equity investment to broaden management, and to enhance marketing and business development activities in the U.S. and Europe.


Safety (reversibility)

Risk Reduction

Fewer Complications


Cost Reduction

Bioterm may become extremely valuable to various players in the healthcare market - especially to leading pharmaceutical companies, healthcare insurers and service providers, and of course, to mothers and babies:

Big Farma

Advanced Treatment

Market Advantage

Competitive Edge

Read More

Health Providers

Cost Reduction

Enhanced Treatment

Fewer Complications

Read More


Superior Treatment

Reduction of Risks

Fewer Complications

Read More


Various scientific case reports on the use of the Preventerm source molecule report no adverse side effects to the mother or infant

Initial tests of Preventerm have shown a 90% efficacy rate in preventing preterm labor – overwhelmingly more effective than any of the currently available treatment modalities

Preventerm stands to decrease the overall expense of preterm infant health care and will reduce infant mortality as well as post-natal complications considerably

We intend to generate revenue through joint and/or strategic collaborations with large pharmaceutical and biotechnology companies in order to further develop our products, jointly facilitate regulatory approval, and subsequently to bring our products to the global markets

A unique investment opportunity: Patented and patent-pending breakthrough drugs Direct solution to a pressing market need Vast expertise in the OB/Gyn industry Several discrete multi-billion dollar markets Strategic value to large pharmaceutical companies